Corbus Pharmaceuticals Holdings Inc experienced a significant price increase of 36.65%, breaking above its 5-day SMA amid a generally weak market, with the Nasdaq-100 down 0.49% and the S&P 500 down 0.28%.
This surge is attributed to the positive results from the Phase 1a clinical trial of CRB-913, which demonstrated a mean weight loss of 2.9% in obese patients, highlighting the drug's potential in obesity management. The upcoming Phase 1b study further validates the efficacy of CRB-913, which is expected to enhance investor confidence and interest in the stock.
The implications of this trial success are significant, as CRB-913's innovative mechanism and strong safety profile position Corbus Pharmaceuticals favorably in the competitive obesity treatment market, potentially leading to increased market share and revenue growth.
Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 46.71 USD with a low forecast of 38.00 USD and a high forecast of 53.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 46.71 USD with a low forecast of 38.00 USD and a high forecast of 53.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.340
Low
38.00
Averages
46.71
High
53.00
Current: 9.340
Low
38.00
Averages
46.71
High
53.00
RBC Capital
Outperform
maintain
$53
2025-12-11
Reason
RBC Capital
Price Target
$53
AI Analysis
2025-12-11
maintain
Outperform
Reason
RBC Capital notes that Corbus Pharmaceuticals has disclosed updates from its Phase I SAD/MAD study of CRB-913, a CB1 receptor inverse agonist, and management also hosted a conference call to discuss the data in detail. Early hints at efficacy and possibility Corbus could navigate a therapeutic window better than prior CB1 efforts should draw attention to this under-the-radar asset, with more robust de-risking data potentially only a few quarters away. At a $35M EV, with a cancer drug in '701 RBC views as low-risk, and a higher-risk but potentially very large-opportunity obesity asset, the firm believes the company is undervalued. The firm has an Outperform rating on the shares with a price target of $53.
Stifel
Stephen Willey
Buy
maintain
$28 -> $32
2025-12-04
Reason
Stifel
Stephen Willey
Price Target
$28 -> $32
2025-12-04
maintain
Buy
Reason
Stifel analyst Stephen Willey raised the firm's price target on Crescent Biopharma to $32 from $28 and keeps a Buy rating on the shares. The firm believes the Kelun deal creates "greater pipeline and CR-001 development and optionality," with Crescent "securing ex-Greater China rights to an ADC with a clinically-validated target antigen and linker/payload and positioning itself to leverage data generated from Kelun's interrogation of CR-001-based combinations with its other ADCs."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRBP
Unlock Now
RBC Capital
Brian Abrahams
Outperform
downgrade
$55 -> $53
2025-11-13
Reason
RBC Capital
Brian Abrahams
Price Target
$55 -> $53
2025-11-13
downgrade
Outperform
Reason
RBC Capital analyst Brian Abrahams lowered the firm's price target on Corbus Pharmaceuticals to $53 from $55 but keeps an Outperform rating on the shares. Following ESMO updates, the potential $500M sales opportunity for '701 in HNSCC and $350M sales opportunity in cervical cancer have been better de-risked, the analyst tells investors in a research note. RBC adds that investors are still not fully appreciating Corbus's potential large out-year sales opportunities across oncology and obesity.
Mizuho
NULL -> Outperform
maintain
$32 -> $39
2025-10-29
Reason
Mizuho
Price Target
$32 -> $39
2025-10-29
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Corbus Pharmaceuticals to $39 from $32 and keeps an Outperform rating on the shares.
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
